Thymagen
A synthetic immunomodulatory dipeptide (Glu-Trp) isolated from the thymic peptide complex Thymalin, studied for T-cell differentiation, anti-aging immune restoration, and anti-inflammatory activity as part of the Khavinson bioregulator system.
What is Thymagen?
Thymagen (also known as Thymogen) is a synthetic dipeptide composed of L-glutamic acid and L-tryptophan (Glu-Trp, single-letter code: EW). It was isolated from the natural calf thymic peptide complex Thymalin by reverse-phase HPLC by Vladimir Khavinson and Vladimir Morozov at the St. Petersburg Institute of Bioregulation and Gerontology. Thymagen is classified as one of the primary active components of Thymalin — the other being the KE dipeptide (Lys-Glu, marketed as Vilon). While Thymalin is a complex extract containing multiple thymic factors, Thymagen represents its isolated immunostimulatory dipeptide, synthesized for pharmaceutical use. It has been registered as a pharmaceutical in Russia since 1990 in three formulations: intramuscular injection, nasal spray, and topical cream. Notably, the D-enantiomer (D-Glu-D-Trp) has the opposite biological effect — acting as an immunosuppressant (marketed as Thymodepressin) — making this one of the rare examples where mirror-image molecules exhibit reciprocal biological activities.
What Thymagen Is Investigated For
Thymagen is investigated primarily for immune restoration in aging and immunodeficiency, T-cell differentiation support, respiratory infection prevention, and broader anti-aging and anti-carcinogenic claims within the Khavinson bioregulator framework. The strongest available evidence is the 30+ years of registered Russian pharmaceutical use since 1990 — including a randomized placebo-controlled study in elderly post-surgical patients showing reduced postoperative complications, a type 1 diabetes study reporting T-lymphocyte differentiation activation, and a military cohort study showing reduced respiratory infection morbidity with intranasal thymogen. A long-duration rat study also demonstrated extended maximum lifespan and reduced spontaneous tumor incidence. The honest caveats are substantial: independent Western replication is essentially absent, no Western-standard RCTs exist in major databases, formal pharmacokinetic modeling has not been done, and the proposed mechanism of direct DNA and histone binding by a dipeptide rests on molecular modeling from the Khavinson group without independent confirmation. The D-enantiomer (D-Glu-D-Trp) has opposite immunosuppressive activity, making stereochemical purity critical — research-chemical supply cannot be assumed equivalent to Russian pharmaceutical-grade product.
History & Discovery
Thymagen — also widely known as Thymogen — emerged from the same Khavinson and Morozov program at the St. Petersburg Institute of Bioregulation and Gerontology that produced the parent Thymalin extract. In the 1980s, after years of clinical work with the heterogeneous calf-thymus preparation, the group used reverse-phase HPLC to fractionate Thymalin and identified the dipeptide L-Glu-L-Trp as a primary immunostimulatory component. They synthesized it as a chemically defined pharmaceutical, registering it in Russia in 1990 in three formulations: intramuscular injection, nasal spray, and topical cream. Thymagen is one of the more concretely defined entries in the Khavinson catalog — a synthesized dipeptide rather than a heterogeneous extract — and it has the additional curiosity that its D-enantiomer (D-Glu-D-Trp, marketed as Thymodepressin) reportedly has the opposite biological activity, an unusual property in peptide pharmacology. Despite over three decades of registered Russian pharmaceutical use, Western clinical adoption is essentially absent and the dipeptide is not approved by any Western regulatory agency. Indexed clinical literature in major databases is sparse; most evidence remains within the Russian research network, and independent Western replication is limited.
How It Works
Thymagen is a two-amino-acid peptide that helps restore immune function by supporting the maturation and activation of T-cells — the immune cells trained in the thymus gland. As the thymus shrinks with age, immune function declines. Thymagen may help compensate by activating T-cell differentiation, reducing immune cell death (apoptosis), enhancing the activity of pathogen-engulfing cells (neutrophils and macrophages), and dampening excessive inflammatory signaling.
Thymagen (L-Glu-L-Trp) exerts immunomodulatory effects through multiple pathways. It activates T-cell differentiation and enhances T-cell recognition of peptide-MHC complexes. The dipeptide modulates intracellular cyclic nucleotide balance — down-regulating cAMP and cGMP catabolism by inhibiting phosphodiesterase activity, thereby increasing intracellular levels and enhancing immune cell responsiveness. In monocyte/macrophage THP-1 cell models, Thymagen (as part of the Khavinson peptide panel) increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases while inhibiting TNF and pro-inflammatory IL-6 expression under LPS stimulation, acting as a natural inducer of TNF tolerance. It reduces monocyte adhesion to activated endothelial cells. In spleen cell studies, Thymagen activates B-lymphocytes through inhibition of apoptosis and stimulation of proliferation. The EW dipeptide has been shown to inhibit ACE2 expression and reduce synthesis of IL-1-beta, IL-6, and TNF-alpha by 1.4-6.0 fold. At the epigenetic level, the Khavinson group proposes that Glu-Trp binds to DNA regulatory regions and histone H1/3 proteins, altering chromatin conformation and gene accessibility in immune-related gene clusters. It also activates neutrophil chemotaxis and phagocytic activity.
Evidence Snapshot
Human Clinical Evidence
Limited but notable. Thymogen has been a registered pharmaceutical in Russia since 1990 with over three decades of clinical use. A double-blind, randomized placebo-controlled study in elderly post-surgical patients showed restored immune parameters and statistically significant reduction in postoperative complications. A clinical study in type 1 diabetes patients reported T-lymphocyte differentiation activation with clinical effect in 94.4% and laboratory effect in 83.3% of patients. A military cohort study showed intranasal and subcutaneous thymogen significantly reduced morbidity, severity, and duration of acute respiratory infections. However, no Western-standard RCTs are indexed in major databases.
Animal / Preclinical
Moderate-to-strong within the Khavinson framework. A well-designed rat study (n=76, 12-month treatment) demonstrated significantly extended maximum lifespan (1048 vs. 949 days, p<0.001), reduced aging rate (0.0041 vs. 0.0071 days-1), and reduced spontaneous tumor incidence — total tumors 1.5x lower, malignant tumors 1.7x lower, and hematopoietic malignancies 3.4x lower. In vitro studies demonstrate TNF tolerance induction, IL-6 suppression, anti-apoptotic effects in lymphocytes, and B-cell activation in spleen models. The EW dipeptide reduced COVID-19-related cytokine synthesis (IL-1-beta, IL-6, TNF-alpha) by 1.4-6.0 fold in cell models.
Mechanistic Rationale
Moderate. T-cell differentiation activation, cyclic nucleotide modulation, anti-inflammatory cytokine regulation, and anti-apoptotic effects have been demonstrated in peer-reviewed studies. The proposed mechanism of direct DNA and histone binding by a dipeptide is supported by molecular modeling from the Khavinson group but has not been independently replicated outside that research program. The reciprocal biological activity of L- and D-enantiomers provides indirect evidence for receptor or target specificity.
Research Gaps & Open Questions
What the current literature has not yet settled about Thymagen:
- 01Independent replication outside the Khavinson research program — even with three decades of registered Russian use, Western laboratories have not reproduced the core efficacy claims under modern trial-methodology standards.
- 02Modern blinded randomized controlled trials in Western populations for any indication — including the immunocorrection, anti-aging, and respiratory infection prevention claims.
- 03Formal pharmacokinetics in humans — absorption (particularly across nasal mucosa), distribution, metabolism, and clearance have not been characterized by Western standards.
- 04Mechanism specificity — the proposed mechanism of direct DNA and histone binding by a dipeptide is supported by molecular modeling from the Khavinson group but has not been independently replicated outside that program.
- 05Long-term safety with cumulative repeated courses across multiple years.
- 06Theoretical cancer-promotion concern — immune stimulation in patients with subclinical malignancy is a class consideration that Russian observational data does not adequately address.
Forms & Administration
In Russia, Thymogen is registered in three pharmaceutical formulations: intramuscular injection (typically 100 mcg daily for 3-10 days), nasal dosed spray, and topical cream. Outside Russia, it is available as a research peptide for subcutaneous injection. Clinical protocols typically involve short courses (5-10 days) repeated periodically. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Russian pharmaceutical protocols use 100 mcg per intramuscular injection per day. Nasal dosed-spray formulations deliver microgram-range doses to mucosal immune tissue. Research-chemical injectable Thymagen sold outside Russia typically follows similar 100–200 mcg dose ranges.
Frequency
Daily, typically morning intramuscular or subcutaneous administration. Nasal spray protocols use one or two daily applications.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
3–10 day courses are the standard Russian protocol, repeated periodically (every few months) rather than continuous use — a characteristic feature of Khavinson protocols.
Protocol Notes
Russian pharmaceutical Thymogen is supplied as lyophilized powder for reconstitution or as pre-formulated nasal spray and topical cream. Research-chemical injectable forms outside Russian pharmaceutical channels are typically lyophilized powder requiring reconstitution in bacteriostatic water. Stereochemical purity matters for this dipeptide more than for most: the L-form is immunostimulatory while the D-form is immunosuppressive, so contamination or labeling errors could meaningfully alter biological effect. Western clinicians do not generally prescribe it, and protocols outside Russia rely on convention and the published Russian recommendations rather than independent dose-finding.
Claims for Thymagen's broader anti-aging, lifespan-extension, and cancer-prevention effects exceed what the evidence base, dominated by single-program Russian research, can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical supply outside Russian pharmaceutical channels is not authorized for human use, and stereochemical purity cannot be assumed.
Timeline of Effects
Onset
Not rigorously characterized by Western-standard pharmacokinetic studies. Russian clinical reports describe immune parameter changes (T-cell counts, cytokine profiles) within a 5–10 day course. Mucosal immune effects from nasal spray (sIgA elevation) have been reported within similar windows.
Peak Effect
Russian protocols measure outcomes at the end of a 3–10 day course and at follow-up over weeks. Subjective effects, when reported by users, are typically described within the course rather than acutely.
After Discontinuation
No documented withdrawal syndrome. Immune parameter changes from a single course are typically transient, fading over weeks to months — which is the rationale for repeated periodic courses in Russian protocols. Long-term effects of cumulative use have not been independently studied outside the Khavinson framework.
Monitoring & Measurement
Bloodwork & Labs
- •CBC with differential — total lymphocytes and CD4 / CD8 subsets
- •hs-CRP
- •Quantitative immunoglobulins (IgG, IgA, IgM)
Functional & Performance Tests
- •Structured illness frequency and duration diary — the honest real-world endpoint given the limited Western evidence base
When to Test
Baseline, 12 weeks, and 24 weeks. Illness diary continuous.
Interpretation & Notes
Thymagen is a Russian-developed Khavinson dipeptide (Glu-Trp) with almost no Western clinical replication. The measurement strategy that makes sense is also the one that produces useful information: a disciplined 6-month infection diary against a baseline immune panel, so you have honest data about whether it did anything in your case. NK-cell flow cytometry and other specialty assays add cost without necessarily adding interpretability here — the Russian publications describe effects on lymphocyte subsets, but the original protocols use methods that are not well-standardized internationally. CBC and immunoglobulin panels are direct-to-consumer via LabCorp, Quest, Marek Health, or Ulta Lab Tests.
Common Questions
Who Thymagen Is NOT For
- •Pregnancy — no adequate reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Active autoimmune disease — immunostimulation in an autoimmune context could theoretically worsen disease activity; requires clinician evaluation.
- •Active or recent-history hematologic malignancy — immune-cell stimulation is theoretically concerning in lymphoid malignancy contexts.
- •Pediatric use — limited safety and developmental data outside Russian clinical practice.
- •Known hypersensitivity to peptide preparations or to excipients. Research-chemical supply quality, sterility, and stereochemical purity cannot be assumed and raise injection-site infection and biological-activity concerns absent from clinic-supplied medication.
Drug & Supplement Interactions
Documented clinical drug interactions for Thymagen are limited; no formal interaction studies meeting Western standards have been published. Theoretical class concerns mirror Thymalin: concurrent use with immunosuppressive agents (corticosteroids at immunosuppressive doses, calcineurin inhibitors, T-cell-targeted biologics) would be expected to oppose Thymagen's intended T-cell-supportive activity and is not consistent with the prescribing rationale for those agents. Russian clinical literature describes adjunctive use with antibiotics, antiviral therapy, and tuberculostatic regimens without flagged interactions, but these reports do not meet modern interaction-study standards. Patients on any regular medication should disclose use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved — registered only in Russia
- • Most clinical data is from Russian research institutions
- • No formal Western-standard toxicology or pharmacokinetic studies
- • No drug interaction studies have been conducted
- • Quality and purity vary by source outside Russian pharmaceutical channels
- • The D-enantiomer (D-Glu-D-Trp) has immunosuppressive effects — stereochemical purity is critical
What We Don't Know
Western clinical trial data is absent. While over 30 years of registered pharmaceutical use in Russia provides a substantial real-world safety record, this has not been replicated in Western regulatory frameworks. No independent dose-escalation studies, formal pharmacokinetic modeling, or long-term safety evaluations meeting Western standards have been published. The precise mechanism of DNA/histone interaction proposed by the Khavinson group remains debated.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A compounding. Sold primarily through research-chemical suppliers not authorized for human use. Unclear whether any US-licensed clinics administer it.
International
Registered as a pharmaceutical in Russia since 1990 in three formulations (IM injection, nasal spray, topical cream) for immunocorrection indications. Limited availability in some CIS states. Not approved by EMA, MHRA, Health Canada, or TGA.
Sports & Competition
Not specifically named on the WADA Prohibited List, but as a parenteral substance without governmental health authority approval in most WADA-code jurisdictions, the WADA S0 catch-all category likely applies for athletes outside Russia.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Thymagen has been independently validated as an immunostimulant by Western research.
Reality
Very little independent Western validation exists. The pharmaceutical has been registered and used in Russia since 1990, but indexed Western clinical trials are essentially absent, and most evidence remains within the Khavinson research program and Russian clinical network.
Myth
Russian pharmaceutical registration since 1990 means Western-equivalent regulatory validation.
Reality
Russian registration reflects an internal regulatory verdict on data assembled within the Russian system, not independent validation under FDA, EMA, MHRA, or other Western regulatory standards. The two processes have different evidence requirements and should not be treated as equivalent.
Myth
Vladimir Khavinson won the Nobel Prize for the peptide bioregulator research underlying Thymagen.
Reality
He did not. Persistent online attributions to a Nobel Prize are inaccurate. The Khavinson group has published extensively, but the body of work has not been recognized at that level by the broader scientific community.
Myth
Research-chemical Thymagen is biologically equivalent to the registered Russian pharmaceutical.
Reality
Stereochemical purity is critical for this dipeptide — the L-form is immunostimulatory while the D-form is immunosuppressive, with reciprocal biological effects. Research-chemical supply quality, identity, and sterility cannot be assumed equivalent to Russian pharmaceutical-grade product, and product testing in this market segment has historically found discrepancies between label and content.
Myth
Because it is just two amino acids, Thymagen is essentially harmless.
Reality
Small molecular size does not imply safety. The dipeptide is reported to modulate immune-cell function and gene expression — exactly the kind of activity that requires careful safety evaluation, particularly in autoimmune contexts and in patients with subclinical malignancy. Safety has to be established by data, not inferred from molecular weight.
Published Research
9 studiesThe Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19
Demonstrated that EW dipeptide targets ACE2 and CYSLTR1 genes, and Thymalin with its EW and KE dipeptides reduced IL-1-beta, IL-6, and TNF-alpha cytokine synthesis by 1.4-6.0 fold in vitro.
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line
Khavinson peptides including Thymagen increased MAP kinase phosphorylation, inhibited TNF and IL-6 in LPS-stimulated monocytes, and reduced monocyte adhesion to endothelium — acting as natural TNF tolerance inducers.
Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity
Demonstrated that L-Glu-L-Trp (Thymogen) and its D-enantiomer (Thymodepressin) exhibit reciprocal biological activities — immunostimulation vs. immunosuppression — a rare phenomenon in peptide pharmacology.
Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process
Demonstrated that Thymogen activates B-lymphocytes in aging spleen tissue through apoptosis inhibition and proliferation stimulation, with age-dependent immunoprotective properties.
Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation
Characterized L-Glu-L-Trp as a naturally occurring thymic immunomodulator and developed lipid/glycosyl conjugates to enhance oral bioavailability, demonstrating improved enzymatic resistance and membrane permeability.
Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
76 female rats treated with L-Glu-L-Trp for 12 months showed extended maximum lifespan (1048 vs. 949 days, p<0.001), reduced aging rate, and significantly lower spontaneous tumor incidence (total tumors 1.5x, malignant 1.7x, hematopoietic 3.4x lower).
Natural and synthetic thymic peptides as therapeutics for immune dysfunction
Khavinson and Morozov describe the isolation of L-Glu-L-Trp from Thymalin by HPLC and the development of Thymogen as a synthetic pharmaceutical, demonstrating T-cell differentiation activation and cytokine modulation.
Thymogen in the treatment of type-1 diabetes mellitus
Comparative study showing thymogen activated T-lymphocyte differentiation in type 1 diabetes patients with secondary immunodeficiency, with clinical effect in 94.4% and laboratory effect in 83.3% of patients.
The clinico-epidemiological efficacy of thymogen in acute respiratory viral infections in a military collective
Intranasal and subcutaneous thymogen in military personnel significantly reduced morbidity rate, severity, and duration of acute respiratory infections including influenza.
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 9PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.